CancerMate is a software that implements an in-silico platform for cancer clinical and pharmaceutical research and therapy. The software enables virtual drug repositioning/development, for fully sustainable scenarios implemented in in-silico replicas (avatars) of patients. CancerMate creates an immersive experience when integrated with augmented reality (AR) tools, strengthening specialists' knowledge and judgment on the outcome of therapy and improves clinical efficiency with a positive impact on costs (for example, avoiding unnecessary clinical costs necessary).

Pitch deck iBMB

Cancer treatments may fail to match specific patient features, causing higher social and economic costs than necessary. There is a market opportunity in the development of tools to predict tumors progression and response to novel treatments, aimed at personalized therapies for cancer patients.

There is a market opportunity in the development of tools to predict tumors progression and response to novel treatments, aimed at personalized therapies for cancer patients

The only project that compares to CancerMate is the Oncosimulator P- medicine (2011-2015 period). This product does not allow for:​ true personalized analyses​, significant reductions of predictions costs, requiring much more maintenance effort . To date, the development and marketing status of the Oncosimulator P-medicine is unknown (no trace in the available market)​.

VR/AR, Cloud computing

All models generated, for each user, will remotely reside on one or more servers. Access and use through user profile, for one month in trial mode, or longer by a fee-for-service model.

• Clinical oncologists and surgeons in hospitals​
• Researchers in pharmaceutical industries​
• Digital imaging diagnostics manufacturers​
• Higher education: oncology and health tech classes

Ospedale di Cremona, IRCSS-CROB, ANSYS France